It can reduce the sensitivity of esophageal cancer to cisplatin chemotherapy and, when highly expressed, can promote tumor cell proliferation and migration while also chemosensitizing DNA damage and downregulating protein expression through the ATM/ATR-p53 signaling pathway 39. This evidence concerns the gene TP53 and esophageal cancer.